Sweden's ChemoTech Q4 sales rise on Animal Care unit strength

Reuters
02/17
Sweden's ChemoTech Q4 sales rise on Animal Care unit strength

Overview

  • Swedish medical tech firm's Q4 net sales rose yr/yr, driven by Animal Care segment

  • Q4 operating cash flow improved significantly compared to last year

  • Company reports strong Animal Care sales and first U.S. order from equine clinic

Outlook

  • ChemoTech plans initial technical tests for next-gen vetIQure platform in 2026

  • Company sees North America as key market opportunity for growth

  • ChemoTech aims to strengthen presence in Europe as market conditions evolve

Result Drivers

  • ANIMAL CARE SALES - Strong Q4 sales in Animal Care segment exceeded expectations despite anticipated seasonal slowdown

  • U.S. MARKET ENTRY - First U.S. order from leading equine clinic in Kentucky marks significant market entry

  • TREATMENT KIT SALES - Cumulative number of treatment kits sold more than doubled from 2024, driven by higher utilization and confidence

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 Sales

SEK 2.65 mln

Q4 EPS

-SEK 0.10

Q4 Operating Cash Flow

-SEK 338,000

Analyst Coverage

  • Wall Street's median 12-month price target for Scandinavian ChemoTech AB is SEK6.30, about 67.6% above its February 16 closing price of SEK3.76

Press Release: ID:nWkr1q9DYr

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

应版权方要求,你需要登录查看该内容

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10